组蛋白乙酰转移酶抑制剂增加了胆碱酯酶和磷酸胆碱酯酶的水平.pdf

UKPMC Funders Group Author Manuscript Cancer Res. Author manuscript; available in PMC 2012 August 15. Published in final edited form as: Cancer Res. 2012 February 15; 72(4): 990–1000. doi:10.1158/0008-5472.CAN-11-2688. U K P M C Histone deacetylase inhibition increases levels of choline kinase F u alpha and phosphocholine facilitating non-invasive imaging in n d e human cancers r s G 1 1 1 3 Mounia Beloueche-Babari , Vaitha Arunan , Helen Troy , Robert H te Poele , Anne- r o 1 1 1 2 Christine Wong Te Fong , L Elizabeth Jackson , Geoffrey S Payne , John R Griffiths , Ian u p 3 3 1,* 1 R Judson , Paul Workman , Martin O Leach , and Yuen-Li Chung A 1 u Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and t h Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, o r Sutton, Surrey SM2 5PT, UK M 2 a Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 ORE, n u UK s c 3 r Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute i p of Cancer Research, Sutton, Surrey SM2 5NG, UK t Abstract Histone deacetylase (HDAC) inhibitors are currently approved for cutaneous T-cell lymphoma and are in mid-late stage trials for other cancers. The HDAC inhibitors LAQ824 and SAHA i